Fig. 6
From: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway
ANXA1 knockdown promoted the inactivation of EGFR signaling and downstream pathways after treatment with gefitinib. A, C BLCA cells were treated with different concentrations of gefitinib (0.1 μM, 1 μM, 10 μM) for 6 h. The levels of EGFR, p-EGFR (Tyr1068), AKT, p-AKT (Ser473), ERK, and p-ERK (Thr202/Tyr204) were measured by Western blot. B, D Densitometric ratios of P-EGFR/GAPDH. Data are presented as the mean ± SD